Business
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
SAN FRANCISCO, February 23, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN® dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy (NCT05997615). These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising a
About this update from Vir Biotechnology, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3057,"height":718,"url":"https://media.zenfs.com/en/business-wire.com/44b7324dc215b7746b400883146b5838"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9uTpG_U21xYbjRPaunbgwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyNTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/44b7324dc215b7746b400883146b5838","width":960,"height":225},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/WBDZN4prk8HIN9ZDOZ_JLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NjQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/44b7324dc215b7746b400883146b5838","width":1200,"height":282}},"lazy":false},{"type":"text","content":"– Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date– Dose-dependent anti-tumor activity was observed, with 82% PSA50 and 53% PSA90 declines and RECIST-evaluable objective responses (45% ORR in 5/11 patients) in ≥3,000 µg/kg Q3W dosing cohorts– Vir Biotechnology to host conference call today at 5:30 p.m. ET / 2:30 p.m. PT– Data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium on February 26 (Oral Abstract #17)","length":597,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, February 23, 2026--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN® dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy (NCT05997615). These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising anti-tumor activity. Data will be presented in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium on February 26 in San Francisco, CA (Oral Abstract #17).","length":729,"tagName":"p"},{"type":"text","content":""We are encouraged by VIR-5500's safety and tolerability profile and the early signals of durable anti-tumor activity in a heavily pre-treated population, which validate our PRO-XTEN...